MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) – ReWalk Robotics, Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading manufacturer of medical robotic technology for people with lower extremity disabilities, announced today that the Federal Social Court has scheduled a hearing to review the decision whether a medical device with an exoskeleton can be classified as directly or indirectly compensating for the loss of function in people with spinal cord injuries or paraplegia. The hearing is scheduled for November 10, 2022.

The court’s decision will create a new national guideline for medical devices with exoskeletons and will apply nationwide to all those with statutory health insurance. The establishment of a legal classification of exoskeletons will provide guidance to both patients and insurance companies and create a reliable legal basis for the application process for the provision of exoskeletons.

“The numerous benefits patients experience from regaining the ability to stand and walk through the use of a ReWalk exoskeleton have made it clear that restoring walking function after spinal cord injury is a basic need,” says Larry Jasinski, CEO of ReWalk Robotics ” The German healthcare system has pioneered the introduction of exoskeletons for people with spinal cord injuries.By introducing a clear classification for medical devices with exoskeletons, the court will provide payers and patients with important national guidance when applying for care and supplies to create a way to provide all authorized users in Germany with access to this innovative technology through an established bidding process. We look forward to the forthcoming decision.”

For more information on ReWalk Robotics and the ReWalk exoskeleton, visit rewalk.com.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for people with lower limb disabilities, as…